Leading Developer and Manufacturer of In Vivo and

Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products > Lipid-based In Vivo Transfection Kit Efficient in vivo delivery of nucleic acids and proteins is possible with the Altogen® Biosystems cationic lipid transfection reagent. This product falls into the category of the versatile in vivo transfection kits that Altogen® Biosystems offers. Degradation of cargo molecules is minimized and delivery efficiency is maximized for any negatively charged molecules (DNA, RNA) Altogen Biosystems 848 Rainbow Blvd #823 Las Vegas NV 89107 USA Telephone 702 349 6103 Fax 702 989 -0841 email techserv@altogen. com

Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products > Lipid-based In Vivo Transfection Kit Lipids refer to a class of molecules that occur naturally and include sterols, waxes, fats, vitamins that are fat soluble, monoglycerides, phospholipids and many others. A positively charged head and one or two hydrocarbon chains encompass the structure of cationic lipids, various models of which are shown. The dynamic between the charged head and phosphate backbone of a nucleic acid allows for DNA condensation. www. wikipedia. org Altogen Biosystems 848 Rainbow Blvd #823 Las Vegas NV 89107 USA Telephone 702 349 6103 Fax 702 989 -0841 email techserv@altogen. com

Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products > Lipid-based In Vivo Transfection Kit Summary All Altogen® In Vivo Transfection Kits supplied with pre-optimized ready-to-run transfection protocols that eliminate the need for extensive transfection testing and optimization experiments Lipid-based in vivo transfection reagent is a proprietary, animal-origin-free formulation of chemically engineered liposomes optimized for si. RNA, sh. RNA, mi. RNA, plasmid DNA, and small protein in vivo delivery. Altogen Biosystems 848 Rainbow Blvd #823 Las Vegas NV 89107 USA Telephone 702 349 6103 Fax 702 989 -0841 email techserv@altogen. com

Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products > Lipid-based In Vivo Transfection Kit Mechanism of Action Cationic lipid reagents provide one of the most robust and effective tool for creating transfection complexes with negatively charged cargo (bind spontaneously to the liposomes that have a positive charge), while proprietary formulation allows to minimize complex size providing effective delivery into target tissues The benefits of the lipid-based in vivo transfection kit include high transfection efficiencies into target tissues, preoptimized protocol, easy to use, and consistent, reproducible results! Altogen Biosystems 848 Rainbow Blvd #823 Las Vegas NV 89107 USA Telephone 702 349 6103 Fax 702 989 -0841 email techserv@altogen. com

Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products > Lipid-based In Vivo Transfection Kit Product Details Lipid-based reagent Complexes are stable in serum for 16 hours Efficient delivery to the heart, lung, liver, pancreas, kidney, and multiple tumor types via systemic administration Efficient si. RNA and plasmid DNA delivery via IV, IT, or direct subcutaneous tumor injection (various tumor types) Minimal toxicity Functionally tested in mice and rats Applicable for plasmid DNA/si. RNA co-injection Developed and manufactured by Altogen Biosystems Modes of administration: • Systemic intravenous (i. v. ) injection • Direct intratumoral (i. t. ) injection • Intraperitoneal (i. p. ) injection Altogen Biosystems 848 Rainbow Blvd #823 Las Vegas NV 89107 USA Telephone 702 349 6103 Fax 702 989 -0841 email techserv@altogen. com

Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products > Lipid-based In Vivo Transfection Kit Tissue-Targeting: Easiest Reagent to Use Combine diluted exogenous nucleic acid material and Altogen® Biosystems Lipid-based Transfection Reagent, vortex, incubate and choose administration route for targeted tissue The experimental animal recipient, the targeted tissue and route of administration are the factors that will determine the amount of exogenous nucleic acids and suggested injection volume. Altogen Biosystems 848 Rainbow Blvd #823 Las Vegas NV 89107 USA Telephone 702 349 6103 Fax 702 989 -0841 email techserv@altogen. com

Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products > Lipid-based In Vivo Transfection Kit Product Details • Our kits are easy to use and effective: Mix, incubate, dilute, and inject! • Our kits allow for sustained m. RNA knockdown after a single si. RNA injection • Target various organs through different administration routes. • There is very low in vivo toxicity and it is safe to use as there is no detectable inflammatory response. • Used for preclinical research worldwide! Altogen Biosystems 848 Rainbow Blvd #823 Las Vegas NV 89107 USA Telephone 702 349 6103 Fax 702 989 -0841 email techserv@altogen. com

Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products > Lipid-based In Vivo Transfection Kit Data Figure 1. Systemic administration (i. v. ) of Lipid-based In Vivo reagent conjugated with si. RNA targeting Lamin A/C m. RNA or non-silencing control si. RNA following the recommended protocol. Tissues were collected and RNA isolated 48 hours after first injection. Samples were analyzed by q. RT-PCR for Lamin A/C gene expression levels. Ribosomal RNA levels were used to normalize the Lamin A/C data. Data are means ± SD (n=6).

Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products > Lipid-based In Vivo Transfection Kit Data Figure 2. Intratumoral administration (i. t. ) of Lipid-based In Vivo reagent conjugated with si. RNA targeting Lamin A/C m. RNA or non-silencing control si. RNA following the recommended protocol. Tissues were collected and RNA isolated 48 hours after first injection. Samples were analyzed by q. RT-PCR for Lamin A/C gene expression levels. Ribosomal RNA levels were used to normalize the Lamin A/C data. Data are means ± SD (n=6).

Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products > Lipid-based In Vivo Transfection Kit Data Figure 3. Systemic administration (i. v. ) of Lipid In Vivo Transfection Reagent conjugated with 80 ug of chemically modified si. RNA targeting Lamin A/C m. RNA or non-silencing control si. RNA following the recommended protocol. Tissues (Liver, Brain, Muscle, Kidney, Tumor, Heart, Spleen, Lung) were collected and total protein fraction isolated 72 hours after first injection. Samples were analyzed by Western Blot Analysis for Lamin A/C gene expression levels.

Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products > Lipid-based In Vivo Transfection Kit Data Figure 4. Systemic administration (i. v. ) of Lipid In Vivo Transfection Reagent conjugated with 80 ug of chemically modified si. RNA targeting Lamin A/C m. RNA or non-silencing control si. RNA following the recommended protocol. Tissues (Liver, Brain, Muscle, Kidney, Tumor, Heart, Spleen, Lung) were collected and total protein fraction isolated 72 hours after first injection. Samples were analyzed by Western Blot Analysis for Lamin A/C gene expression levels.

Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products > Lipid-based In Vivo Transfection Kit Data Figure 5. Systemic administration (i. v. ) of Lipid In Vivo Transfection Reagent conjugated with 80 ug of chemically modified si. RNA targeting Lamin A/C m. RNA or non-silencing control si. RNA following the recommended protocol. Tissues (Liver, Brain, Muscle, Kidney, Tumor, Heart, Spleen, Lung) were collected and total protein fraction isolated 72 hours after first injection. Samples were analyzed by Western Blot Analysis for Lamin A/C gene expression levels.

Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products > Lipid-based In Vivo Transfection Kit Data Figure 6. Systemic administration (i. v. ) of Lipid In Vivo Transfection Reagent conjugated with 80 ug of chemically modified si. RNA targeting Lamin A/C m. RNA or non-silencing control si. RNA following the recommended protocol. Tissues (Liver, Brain, Muscle, Kidney, Tumor, Heart, Spleen, Lung) were collected and total protein fraction isolated 72 hours after first injection. Samples were analyzed by Western Blot Analysis for Lamin A/C gene expression levels.

Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products > Lipid-based In Vivo Transfection Kit Summary Lipid-based reagent Complexes are stable in serum for 16 hours Efficient delivery to the heart, lung, liver, pancreas, kidney, and multiple tumor types via systemic administration Efficient si. RNA and plasmid DNA delivery via IV, IP, and direct subcutaneous tumor injection (various tumor types) Minimal toxicity Functionally tested in mice and rats Applicable for plasmid DNA/si. RNA co-injection Developed and manufactured by Altogen Biosystems 848 Rainbow Blvd #823 Las Vegas NV 89107 USA Telephone 702 349 6103 Fax 702 989 -0841 email techserv@altogen. com